Bremamectin süstelahus أستونيا - الإستونية - Ravimiamet

bremamectin süstelahus

bremer pharma gmbh - ivermektiin - süstelahus - 10mg 1ml 250ml 1tk; 10mg 1ml 100ml 1tk

Multivit B comp. süstelahus أستونيا - الإستونية - Ravimiamet

multivit b comp. süstelahus

bremer pharma gmbh - tiamiin+riboflaviin+dekspantenool+tsüanokobalamiin+pangaamhape+püridoksiin - süstelahus - 10mg+4mg+2mg+0,01mg+50mg+4mg 1ml 50ml 1tk; 10mg+4mg+2mg+0,01mg+50mg+4mg 1ml 100ml 1tk

Ferrum 10% + B12 süstelahus أستونيا - الإستونية - Ravimiamet

ferrum 10% + b12 süstelahus

bremer pharma gmbh - rauddekstraan+tsüanokobalamiin - süstelahus - 100mg+1,5mcg 1ml 250ml 1tk

Tulaject süstelahus أستونيا - الإستونية - Ravimiamet

tulaject süstelahus

alivira animal health limited - tulatromütsiin - süstelahus - 100mg 1ml 250ml 1tk

Celsunax الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. täiskasvanud patsientidel, et aidata eristada arvatav dementsus koos lewy kehad alzheimeri tõbi.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.